
Geir Olav Hjortland
- Consultant; MD, PhD
Responsible for: Neuroendocrine cancer
Responsible for: Neuroendocrine Cancer
Publications 2023
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 35 (4), e13256
DOI 10.1111/jne.13256, PubMed 37017614
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
JCO Precis Oncol, 7, e2200336
DOI 10.1200/PO.22.00336, PubMed 36753687
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre randomised controlled NeoRes II trial
Ann Oncol (in press)
DOI 10.1016/j.annonc.2023.08.010, PubMed 37657554
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 30 (10)
DOI 10.1530/ERC-23-0057, PubMed 37410378
Publications 2022
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045
Volumetric parameters from [18 F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 34 (7), e13170
DOI 10.1111/jne.13170, PubMed 35729738
Publications 2021
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
J Neuroendocrinol, 33 (5), e12967
DOI 10.1111/jne.12967, PubMed 33769624
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 29 (1), 1-14
DOI 10.1530/ERC-21-0152, PubMed 34647903
Publications 2020
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
PLoS One, 15 (12), e0243900
DOI 10.1371/journal.pone.0243900, PubMed 33315908
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations
Neuroendocrinology, 111 (9), 883-894
DOI 10.1159/000511905, PubMed 33002892
Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Ann Surg, 272 (5), 684-689
DOI 10.1097/SLA.0000000000004340, PubMed 32833767
Publications 2018
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Med Oncol, 35 (4), 47
DOI 10.1007/s12032-018-1103-x, PubMed 29511910
International comparison of treatment strategy and survival in metastatic gastric cancer
BJS Open, 3 (1), 56-61
DOI 10.1002/bjs5.103, PubMed 30734016
North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
Eur J Surg Oncol, 44 (12), 1982-1989
DOI 10.1016/j.ejso.2018.09.014, PubMed 30343998
Publications 2017
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
PLoS One, 12 (11), e0187667
DOI 10.1371/journal.pone.0187667, PubMed 29112960
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Eur J Surg Oncol, 43 (9), 1682-1689
DOI 10.1016/j.ejso.2017.04.010, PubMed 28522174
Publications 2014
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568
Publications 2011
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070
Publications 2009
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
Publications 2004
Glioma biology and experimental therapy: targeted treatment of human gliomas with immunotoxins in representative animal models, and the role of plasminogen activator inhibitor-1 in glioma invasion and growth
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 183, 1 b. (flere pag.)
BIBSYS 041384814, ISBN 82-8072-131-2
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
J Neurosurg, 100 (2), 320-7
DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
Exp Cell Res, 294 (1), 130-9
DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508
Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum
Biochem Biophys Res Commun, 322 (2), 452-7
DOI 10.1016/j.bbrc.2004.07.132, PubMed 15325251
Publications 2003
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717
Publications 2002
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102
Publications 2001
Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines
Lasers Med Sci, 16 (4), 276-83
DOI 10.1007/pl00011364, PubMed 11702633
Publications 1999
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165